[30 May 2012]
Products Affected - Description
Triamterene and Hydrochlorothiazide capsules, Sandoz
50 mg/25 mg, 100 count (NDC 00781-2715-01) - temporarily unavailable
Reason for the Shortage
- Watson could not provide a reason for the shortage.
- Sandoz states the shortage is due to a raw material shortage and capacity issues.
Available Products
Dyazide capsules, GSK
37.5 mg/25 mg, 100 count (NDC 00007-3650-22)
37.5 mg/25 mg, 1000 count (NDC 00007-3650-30)
Maxzide tablets, Mylan
37.5 mg/25 mg, 100 count (NDC 00378-0464-01)
75 mg/50 mg, 100 count (NDC 00378-0460-01)
Triamterene and Hydrochlorothiazide capsules, Mylan
37.5 mg/25 mg, 100 count (NDC 00378-2537-01)
37.5 mg/25 mg, 1000 count (NDC 00378-2537-10)
Triamterene and Hydrochlorothiazide tablets, Mylan
37.5 mg/25 mg, 100 count (NDC 00378-1352-01)
37.5 mg/25 mg, 500 count (NDC 00378-1352-05)
75 mg/50 mg, 100 count (NDC 00378-1355-01)
75 mg/50 mg, 500 count (NDC 00378-1355-05)
Triamterene and Hydrochlorothiazide capsules, Sandoz
37.5 mg/25 mg, 100 count (NDC 00781-2074-01)
37.5 mg/25 mg, 1000 count (NDC 00781-2074-10)
Triamterene and Hydrochlorothiazide tablets, Sandoz
37.5 mg/25 mg, 100 count (NDC 00781-1123-01)
37.5 mg/25 mg, 500 count (NDC 00781-1123-05)
75 mg/50 mg, 100 count (NDC 00781-1008-01)
75 mg/50 mg, 500 count (NDC 00781-1008-05)
Triamterene and Hydrochlorothiazide tablets, UDL
75 mg/50 mg, unit dose, 100 count (NDC 51079-0433-20)
Triamterene and Hydrochlorothiazide capsules, UDL
37.5 mg/25 mg, unit dose, 100 count (NDC 51079-0935-20)
Triamterene and Hydrochlorothiazide tablets, Watson
37.5 mg/25 mg, 100 count (NDC 00591-0424-01)
37.5 mg/25 mg, 500 count (NDC 00591-0424-05)
75 mg/50 mg, 100 count (NDC 00591-0348-01)
75 mg/50 mg, 500 count (NDC 00591-0348-05)
Estimated Resupply Dates
Sandoz has triamterene and hydrochlorothiazide 50 mg/25 mg capsules in 100 count temporarily unavailable and the company cannot estimate a release date. All other triameterene and hydrochlorothiazide presentations are available.
Updated
May 30, 2012; May 18, 2012; April 24, 2012; April 11, 2012; March 12, 2012; March 2, 2012; January 19, 2012; January 10, 2012; January 6, 2012; November 16, 2011; November 4, 2011; October 18, 2011; September 21, 2011; September 1, 2011; August 3, 2011; July 21, 2011; June 29, 2011; June 15, 2011; June 2, 2011; May 25, 2011; May 3, 2011; April 20, 2011; April 15, 2011; March 29, 2011, University of Utah, Drug Information Service. Copyright 2012, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins